research use only
Cat.No.S4772
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor TRP Channel Cholinesterase (ChE) GluR |
|---|---|
| Other GABA Receptor Inhibitors | Dihydromyricetin CGP52432 Oxiracetam Ginkgolide A Pentylenetetrazol 4-Aminobutyric acid (GABA) Emamectin Benzoate Nefiracetam Piracetam Bemegride |
| Molecular Weight | 208.25 | Formula | C12H16O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 2883-98-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | trans-Asarone | Smiles | CC=CC1=CC(=C(C=C1OC)OC)OC | ||
|
In vitro |
DMSO
: 41 mg/mL
(196.87 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| In vitro |
α-asarone possesses an endothelium-dependent vasodilation property, and in normal HUVEC-derived EA.hy926 cells, α-asarone has been shown to upregulate the expression of phosphorylated eNOS (Ser1177), causing an increase in the production of NO. It protects against injury to endothelial cells by attenuating Ang II-mediated changes in intracellular ROS/NO.
|
|---|---|
| In vivo |
Alpha-Asarone treatment alleviates locomotor hyperactivity in Fmr1 KO mice. It improves m1 mAChR expression and up-regulates the ACh levels in the striatum. Its treatment also attenuates the increased striatal AChE activity in Fmr1 KO mice. Alpha-asarone has been reported to have a beneficial effect in cognitive impairment induced by dysfunction of the cholinergic system in the brain through inhibition of AChE activity. Of all the doses tested (2, 10, 40, 80 and 120 mg/kg) in rats, 10 mg/kg α-Asarone improves the quality of sleep, as indicated by an increased NREM bout duration, reduced arousal index, and decreased bout frequencies of NREM sleep and wakefulness. A marginal decrease in the hypothalamic and body temperatures is also observed. Higher doses, on the other hand, not only reduce the quantity and quality of sleep, but also produce hypothermia.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.